tradingkey.logo

Zymeworks rises after unveiling leadership changes

ReutersJan 12, 2026 2:40 PM

Shares of drug developer Zymeworks ZYME.O rise 2.3% to $23.70

Co says it has appointed investment industry veteran Brian Cherry to its board of directors

Cherry previously served as managing partner at private equity firm Oak Hill Capital - ZYME

Adds Dr. Sabeen Mekan to become Chief Medical Officer on February 1, replacing Dr. Jeff Smith

Mark Hollywood promoted to EVP and COO; five new VPs named to strengthen leadership team - ZYME

Says Chief Financial and Business Officer Leone Patterson and General Counsel Daniel Dex to exit in Q1

CEO Kenneth Galbraith to serve as acting CFO until successor is appointed - ZYME

As of last close, stock up ~80% over the past year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI